作者
Robert M Samstein, Chung-Han Lee, Alexander N Shoushtari, Matthew D Hellmann, Ronglai Shen, Yelena Y Janjigian, David A Barron, Ahmet Zehir, Emmet J Jordan, Antonio Omuro, Thomas J Kaley, Sviatoslav M Kendall, Robert J Motzer, A Ari Hakimi, Martin H Voss, Paul Russo, Jonathan Rosenberg, Gopa Iyer, Bernard H Bochner, Dean F Bajorin, Hikmat A Al-Ahmadie, Jamie E Chaft, Charles M Rudin, Gregory J Riely, Shrujal Baxi, Alan L Ho, Richard J Wong, David G Pfister, Jedd D Wolchok, Christopher A Barker, Philip H Gutin, Cameron W Brennan, Viviane Tabar, Ingo K Mellinghoff, Lisa M DeAngelis, Charlotte E Ariyan, Nancy Lee, William D Tap, Mrinal M Gounder, Sandra P D’Angelo, Leonard Saltz, Zsofia K Stadler, Howard I Scher, Jose Baselga, Pedram Razavi, Christopher A Klebanoff, Rona Yaeger, Neil H Segal, Geoffrey Y Ku, Ronald P DeMatteo, Marc Ladanyi, Naiyer A Rizvi, Michael F Berger, Nadeem Riaz, David B Solit, Timothy A Chan, Luc GT Morris
发表日期
2019/2
期刊
Nature genetics
卷号
51
期号
2
页码范围
202-206
出版商
Nature Publishing Group US
简介
Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers, but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor mutational burden (TMB) may predict clinical response to ICI. To examine this association more broadly, we analyzed the clinical and genomic data of 1,662 advanced cancer patients treated with ICI, and 5,371 non-ICI-treated patients, whose tumors underwent targeted next-generation sequencing (MSK-IMPACT). Among all patients, higher somatic TMB (highest 20% in each histology) was associated with better overall survival. For most cancer histologies, an association between higher TMB and improved survival was observed. The TMB cutpoints associated with improved survival varied markedly between cancer types. These data indicate that TMB is associated with improved survival in patients receiving ICI across a wide variety …
学术搜索中的文章
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann… - Nature genetics, 2019